Related Articles
Mediastinal and hilar sarcoid‑like reaction in a patient treated with dabrafenib and trametinib for metastatic melanoma: A case report and review of the literature
Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first‑line therapy for BRAF‑mutated metastatic melanoma
Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells
Musculoskeletal adverse reactions after immunotherapy for cancer: A case series
Potential dual synergy between electrochemotherapy and sequence of immunotherapies in metastatic melanoma: A case report